Focus: Palvella Therapeutics is a publicly-traded, small-molecule focused biotech developing treatments for rare dermatologic and genetic disorders. The company operates with a lean R&D budget and is advancing dual lead programs (PTX-022 and QTORIN) across multiple rare disease indications.
Profile data last refreshed 13h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Palvella Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Palvella Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Palvella Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP - MarketBeat
36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella Therapeutics (NASDAQ: PVLA) COO sells 4,302 shares under 10b5-1 plan Stock Titan
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - Kalkine
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates Kalkine
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - kalkine.ca
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates kalkine.ca
Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA MarketBeat
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel - Seeking Alpha
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel Seeking Alpha
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Showing 5 of 6 publications